Kyle Alspach shares on bizjournals.com that there was biotech boom of venture capital (VC) backed IPOs during the second quarter of 2013. Out of the 21 IPOs funded by VCs, thirteen were categorized as life science related and eleven of those thirteen were biotech. Two of the larger companies included were Cambridge based Bluebird Bio focused on gene therapies, and Epizyme, an oncology company. The 21 VC backed IPOs more than doubled the Q1 eight IPOs encouraging executives in these fields. Mark Heesen, president of the National Venture Capital Association (NVCA), commented “We have been predicting an IPO pickup in the second half of 2013 and it appears as if this momentum has begun, driven by the strong biotechnology offerings.” Now the industry must fight against its past second half of the year slumps, due to negative externalities. For the full article, click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.